4.6 Review

Low-Cost Optical Assays for Point-of-Care Diagnosis in Resource-Limited Settings

Journal

ACS SENSORS
Volume 6, Issue 6, Pages 2108-2124

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acssensors.1c00669

Keywords

lateral flow assays; low-cost; paper-based sensors; paper-based analytical devices; resource-limited settings; SARS-CoV-2; on-site testing; thread-based sensors; point-of-care medical devices

Funding

  1. Engineering and Physical Sciences Research Council (EPSRC) [EP/T013567/1]
  2. Fundamental Research Funds for the Central Universities of China [YJ202152]
  3. Royal Academy NewtonKatip Celebi Transforming Systems Through Partnership award [120N019]
  4. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [404478562]
  5. Alexander von Humboldt Research Fellowship for Experienced Researchers
  6. Marie Sklodowska-Curie Individual Fellowship [101003361]
  7. EPSRC [EP/T013567/1] Funding Source: UKRI

Ask authors/readers for more resources

Readily deployable, low-cost point-of-care medical devices are urgently needed in resource-poor settings to screen various chemical and biological analytes for rapid diagnostics, benefiting public health in areas with limited access to healthcare.
Readily deployable, low-cost point-of-care medical devices such as lateral flow assays (LFAs), microfluidic paper-based analytical devices (mu PADs), and microfluidic thread-based analytical devices (mu TADs) are urgently needed in resource-poor settings. Governed by the ASSURED criteria (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverability) set by the World Health Organization, these reliable platforms can screen a myriad of chemical and biological analytes including viruses, bacteria, proteins, electrolytes, and narcotics. The Ebola epidemic in 2014 and the ongoing pandemic of SARS-CoV-2 have exemplified the ever-increasing importance of timely diagnostics to limit the spread of diseases. This review provides a comprehensive survey of LFAs, mu PADs, and mu TADs that can be deployed in resource-limited settings. The subsequent commercialization of these technologies will benefit the public health, especially in areas where access to healthcare is limited.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available